SEA Stories

Prostate Cancer Panel Discussion and Webcast on Advanced Prostate Cancer

Presented by: Bayer
Sponsored by: Dendreon and Janssen Oncology
In-Kind Sponsor: Los Padres

Guest Speakers:

  • Dr. Edwin Morales - Urology Specialist, San Antonio
  • Dr. Michael Liss - Urologist, Urologic Oncologist, and Lead Prostate Cancer Researcher at UT Health, San Antonio
  • Dr. Vijay K. Gunuganti - Medical Oncologist at Texas Oncology
  • Moderator: Dr. Juan A. Reyna - Staff Physician at Audie L. Murphy Memorial VA Hospital; and Clinical Faculty at UT Health

View the full video by clicking on the image below; or scroll down to access links to short video segments about specific content presented at the event.

Click any link listed below to go straight to that segment of the video:

  • 0:01 - Introduction - Terri Likowski, Us TOO Program Director - Support Group Services
  • 0:50 - Johnny Staha - Support Group Leader - San Antonio, TX
  • 1:07 - Chuck Strand - CEO, Us TOO International
  • 3:04 - Intro to Dr. Juan A. Reyna
  • 4:44 - Dr. Juan A. Reyna - Staff Physician at Audie L. Murphy Memorial VA Hospital; and Clinical Faculty at UT Health
  • 10:00 - Intro to Dr. Edwin Morales
  • 10:56 - Dr. Edwin Morales - Urology Specialist, San Antonio
  • 11:01 - Prostate Cancer Overview, Definitions, Terms
  • 11:52 - Biochemical Recurrence
  • 14:29 - (Non) Metastatic Castrate Resistant Prostate Cancer
  • 17:52 - The Androgen Receptor Axis
  • 20:47 - Androgen Deprivation Therapy
  • 21:17 - After ADT
  • 23:00 - Options for Rising PSA After CAB/AAW
  • 23:44 - Asymptomatic Non - Metastatic Castrate Resistant Prostate Cancer
  • 26:36 - Options for Asymptomatic Non - Metastatic Castrate Resistant Prostate Cancer
  • 32:16 - The "New" Natural History of Prostate Cancer
  • 33:45 - Intro to Dr. Vijay Gunuganti
  • 34:26 - Dr. Vijay Gunuganti - Oncologist at Texas Oncology
  • 35:03 - Lifetime Probability of Developing Cancer
  • 36:07 - Multidisciplinary Team Approach to PCa Management
  • 37:02 - Treatment for CRPC
  • 37:24 - Early Metastatic Prostate Cancer or Hormone Sensitive Prostate Cancer
  • 37:58 - The CHAARTED Hypotheses
  • 38:45 - LATITUDE Trial
  • 39:19 - STAMPEDE Trial
  • 39:33 - Results of Androgen Removal
  • 40:17 - Castrate Resistant Metastatic Prostate Cancer or Hormone Refractory Prostate Cancer
  • 40:59 - Enzalutamide
  • 41:47 - Abiraterone
  • 42:28 - Metastatic Bone Lesions
  • 43:39 - Xofigo
  • 44:10 - Phase III ALSYMPCA Study Design: Patient Eligibility
  • 45:38 - Treatment of Symptomatic, Hormone Refractory Metastatic Disease with Chemotherapy
  • 46:52 - Side Effects of Chemotherapy
  • 48:07 - Currently Approved Therapy for Advanced Prostate Cancer
  • 49:48 - Intro to Dr. Michael Liss
  • 50:52 - Dr. Michael Liss - Urologist, Urologic Oncologist, and Lead Prostate Cancer Researcher at UT Health, San Antonio
  • 51:56 - Screening, PSA Testing, At - Risk Groups
  • 54:35 - African American Men, Family History
  • 55:18 - Individualized Risk Assessment Approach, Shared Decision Making
  • 57:20 - Hereditary Prostate Cancer
  • 58:43 - BRCA
  • 58:54 - Genetics - Risk Using SNPs
  • 59:50 - Functional vs. Non - Functional Genes
  • 1:00:31 - Prostate Genetic Score
  • 1:01:04 - Genomics for Treatment Decisions
  • 1:04:56 - Future of Clinical Trials
  • 1:06:11 - Prostate Imaging - MRI
  • 1:08:29 - Software Detection Technologies, Restricted Spectrum Imaging
  • 1:09:08 - PET/CT Imaging
  • 1:10:32 - Oligometastatic Prostate Cancer Clinical Trials
  • 1:12:35 - Q&A

CLICK HERE to donate to our Holiday Hope Campaign to provide the prostate cancer community with support, education, and advocacy at no charge.